FCS Physicians Driving Progress in Cancer Immunotherapy

Studies Selected for Presentation at Global Gathering

Fort Myers, Fla., November 5, 2025 –  Results of early-phase clinical research conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) will be presented this week at the Society for Immunotherapy of Cancer (SITC) annual meeting, the premier international conference dedicated to advancing cancer immunotherapy.

FCS President & Managing Physician Lucio N. Gordan, MD said, “We’re proud to contribute to groundbreaking research and to be part of this opportunity to share insights, advance immunotherapy, and help shape the future of effective cancer treatment.”

The following FCS physician investigators are co-authors of research abstracts being presented during poster presentations:

Cesar Augusto Perez, MD,  director of drug development, Sarah Cannon Research Institute (SCRI) at FCS  –  First-in-human phase 1/2 study of the integrin αvβ8-blocking antibody CRB-601 in patients with solid tumors (Abstract 582) and ctDNA as a Potential Surrogate Biomarker for Response to Combination Vilastobart and Atezolizumab in Heavily Pretreated Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (NCT04896697) (Abstract 541)

Judy Wang, MD, FCS associate director of drug development –  A phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TNG260 in combination with pembrolizumab in patients with STK11-mutated advanced solid tumors (Abstract 561)

FCS provides access to advanced clinical trial options across 29 locations in Florida, bringing promising therapies closer to home for cancer patients. Over 110 new early-phase and 40 late-phase studies are launched annually. FCS has played a vital role in the development of numerous cancer drugs approved by the U.S. Food and Drug Administration (FDA).

A longstanding partnership with Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, provides patients with access to a comprehensive listing of clinical trials available in the U.S. Additionally, a partnership with Paradigm Health, Inc. helps streamline and accelerate matching patients to available clinical trials.

Accepted SITC Annual Meeting abstracts will be published in the Journal for ImmunoTherapy of Cancer (JITC) as a supplement on November 4, 2025.